Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) (“Roclanda®”) has received marketing authorisation from the Medicines and Healthca